BDSX
Biodesix, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$26.18
−1.11%Year over year
Reported trailing growth
- Revenue
- +34.5%
- EBITDA
- +49.1%
- EBIT
- +39.4%
- EPS
- +44.1%
- Free cash flow
- +34.9%
- Operating cash flow
- +33.8%
Forward estimates
Based on analyst estimates
- Revenue
- +18.4%
- EBITDA
- +33.5%
- EPS
- +25.6%
Three-year CAGR
- Revenue
- +32.3%
- EBITDA
- +24.9%
- EBIT
- +19.5%
- Net income
- +17.9%
- EPS
- +29.5%
- Free cash flow
- +54.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026